# Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

> **NCT04765098** · PHASE2 · RECRUITING · sponsor: **AHS Cancer Control Alberta** · enrollment: 60 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04765098
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-28
- **Primary completion:** 2026-12
- **Final completion:** 2027-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04765098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04765098, "Tamoxifen Versus Etoposide After First Recurrence in GBM Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04765098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*